JP2018503399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503399A5 JP2018503399A5 JP2017556515A JP2017556515A JP2018503399A5 JP 2018503399 A5 JP2018503399 A5 JP 2018503399A5 JP 2017556515 A JP2017556515 A JP 2017556515A JP 2017556515 A JP2017556515 A JP 2017556515A JP 2018503399 A5 JP2018503399 A5 JP 2018503399A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- miac
- cell
- optionally
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims description 72
- 108091007433 antigens Proteins 0.000 claims description 72
- 102000036639 antigens Human genes 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 58
- 239000012636 effector Substances 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 210000002865 immune cell Anatomy 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 42
- 102000005962 receptors Human genes 0.000 claims description 37
- 108020003175 receptors Proteins 0.000 claims description 37
- 239000012634 fragment Substances 0.000 claims description 32
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 18
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 18
- 108091008042 inhibitory receptors Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 13
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 13
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 claims description 12
- 201000005962 mycosis fungoides Diseases 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 11
- 108010043610 KIR Receptors Proteins 0.000 claims description 10
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 10
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 9
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 9
- 108010074328 Interferon-gamma Proteins 0.000 claims description 9
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 8
- 102100024263 CD160 antigen Human genes 0.000 claims description 8
- 102100027207 CD27 antigen Human genes 0.000 claims description 8
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 8
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102100037850 Interferon gamma Human genes 0.000 claims description 8
- 102100020873 Interleukin-2 Human genes 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 8
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 8
- 206010029260 Neuroblastoma Diseases 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 102000001398 Granzyme Human genes 0.000 claims description 7
- 108060005986 Granzyme Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 6
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 6
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims description 6
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 6
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 6
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 230000003827 upregulation Effects 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 102000006495 integrins Human genes 0.000 claims description 5
- 108010044426 integrins Proteins 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 4
- 206010061424 Anal cancer Diseases 0.000 claims description 4
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
- 206010073360 Appendix cancer Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- -1 CC123 Proteins 0.000 claims description 4
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 201000009047 Chordoma Diseases 0.000 claims description 4
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 4
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims description 4
- 208000006402 Ductal Carcinoma Diseases 0.000 claims description 4
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 108060006698 EGF receptor Proteins 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010014967 Ependymoma Diseases 0.000 claims description 4
- 102100033919 Ephrin-A2 Human genes 0.000 claims description 4
- 108010043942 Ephrin-A2 Proteins 0.000 claims description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 4
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 102000003693 Hedgehog Proteins Human genes 0.000 claims description 4
- 108090000031 Hedgehog Proteins Proteins 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 4
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims description 4
- 101000972276 Homo sapiens Mucin-5B Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 4
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims description 4
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 4
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 4
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims description 4
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 4
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 4
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 claims description 4
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 4
- 206010062038 Lip neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 4
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 4
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 102100023123 Mucin-16 Human genes 0.000 claims description 4
- 102100022494 Mucin-5B Human genes 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims description 4
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 4
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 4
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 4
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 4
- 206010034299 Penile cancer Diseases 0.000 claims description 4
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 4
- 206010073334 Rhabdoid tumour Diseases 0.000 claims description 4
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 4
- 208000021388 Sezary disease Diseases 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102100033447 T-lymphocyte surface antigen Ly-9 Human genes 0.000 claims description 4
- 206010043276 Teratoma Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 206010043515 Throat cancer Diseases 0.000 claims description 4
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 101150074789 Timd2 gene Proteins 0.000 claims description 4
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 4
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 4
- 206010046392 Ureteric cancer Diseases 0.000 claims description 4
- 206010046431 Urethral cancer Diseases 0.000 claims description 4
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000005969 Uveal melanoma Diseases 0.000 claims description 4
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 4
- 206010047741 Vulval cancer Diseases 0.000 claims description 4
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 4
- 208000008383 Wilms tumor Diseases 0.000 claims description 4
- 201000011165 anus cancer Diseases 0.000 claims description 4
- 208000021780 appendiceal neoplasm Diseases 0.000 claims description 4
- 208000001119 benign fibrous histiocytoma Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000014616 embryonal neoplasm Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 208000024519 eye neoplasm Diseases 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000024348 heart neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 239000000710 homodimer Substances 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 210000000244 kidney pelvis Anatomy 0.000 claims description 4
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000006721 lip cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 4
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 claims description 4
- 201000008026 nephroblastoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000008106 ocular cancer Diseases 0.000 claims description 4
- 201000002575 ocular melanoma Diseases 0.000 claims description 4
- 201000006958 oropharynx cancer Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000003154 papilloma Diseases 0.000 claims description 4
- 208000029211 papillomatosis Diseases 0.000 claims description 4
- 208000007312 paraganglioma Diseases 0.000 claims description 4
- 208000028591 pheochromocytoma Diseases 0.000 claims description 4
- 208000010916 pituitary tumor Diseases 0.000 claims description 4
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 4
- 208000037968 sinus cancer Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000002314 small intestine cancer Diseases 0.000 claims description 4
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 208000008732 thymoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 206010046885 vaginal cancer Diseases 0.000 claims description 4
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 201000005102 vulva cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 3
- 208000021309 Germ cell tumor Diseases 0.000 claims description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 3
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 3
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 3
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims description 3
- 201000008298 histiocytosis Diseases 0.000 claims description 3
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 3
- 201000000564 macroglobulinemia Diseases 0.000 claims description 3
- 208000037830 nasal cancer Diseases 0.000 claims description 3
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims description 2
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims description 2
- 108700012439 CA9 Proteins 0.000 claims description 2
- 102100038077 CD226 antigen Human genes 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 2
- 102100025222 CD63 antigen Human genes 0.000 claims description 2
- 108010062802 CD66 antigens Proteins 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102000000905 Cadherin Human genes 0.000 claims description 2
- 108050007957 Cadherin Proteins 0.000 claims description 2
- 102100029968 Calreticulin Human genes 0.000 claims description 2
- 108090000549 Calreticulin Proteins 0.000 claims description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 claims description 2
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102100034573 Desmoglein-4 Human genes 0.000 claims description 2
- 101710183213 Desmoglein-4 Proteins 0.000 claims description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 2
- 102100038083 Endosialin Human genes 0.000 claims description 2
- 101710144543 Endosialin Proteins 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 2
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims description 2
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims description 2
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims description 2
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 claims description 2
- 101000945340 Homo sapiens Killer cell immunoglobulin-like receptor 2DS1 Proteins 0.000 claims description 2
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 claims description 2
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 claims description 2
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 claims description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 2
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims description 2
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims description 2
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims description 2
- 101000972273 Homo sapiens Mucin-7 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 claims description 2
- 101000752245 Homo sapiens Rho guanine nucleotide exchange factor 5 Proteins 0.000 claims description 2
- 101000650817 Homo sapiens Semaphorin-4D Proteins 0.000 claims description 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 2
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims description 2
- 101150069255 KLRC1 gene Proteins 0.000 claims description 2
- 101150074862 KLRC3 gene Proteins 0.000 claims description 2
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims description 2
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims description 2
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 claims description 2
- 102100033631 Killer cell immunoglobulin-like receptor 2DS1 Human genes 0.000 claims description 2
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 claims description 2
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 claims description 2
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 claims description 2
- 101710131918 Killer cell lectin-like receptor subfamily B member 1A Proteins 0.000 claims description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims description 2
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims description 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 2
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100034263 Mucin-2 Human genes 0.000 claims description 2
- 102100022497 Mucin-3A Human genes 0.000 claims description 2
- 102100022693 Mucin-4 Human genes 0.000 claims description 2
- 102100022492 Mucin-7 Human genes 0.000 claims description 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 102100022701 NKG2-E type II integral membrane protein Human genes 0.000 claims description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 2
- 101100291452 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MMS1 gene Proteins 0.000 claims description 2
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 2
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims description 2
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 2
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 102000004584 Somatomedin Receptors Human genes 0.000 claims description 2
- 108010017622 Somatomedin Receptors Proteins 0.000 claims description 2
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims description 2
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims description 2
- 101800001271 Surface protein Proteins 0.000 claims description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 101710114141 T-lymphocyte surface antigen Ly-9 Proteins 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 230000004611 cancer cell death Effects 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 210000003026 hypopharynx Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103402P | 2015-01-14 | 2015-01-14 | |
| US62/103,402 | 2015-01-14 | ||
| PCT/US2016/013291 WO2016115274A1 (en) | 2015-01-14 | 2016-01-13 | Multispecific immunomodulatory antigen-binding constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018503399A JP2018503399A (ja) | 2018-02-08 |
| JP2018503399A5 true JP2018503399A5 (https=) | 2019-02-28 |
Family
ID=56406350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556515A Withdrawn JP2018503399A (ja) | 2015-01-14 | 2016-01-13 | 多特異性免疫調節抗原結合構築物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180318417A1 (https=) |
| EP (1) | EP3245227A4 (https=) |
| JP (1) | JP2018503399A (https=) |
| CN (1) | CN107614522A (https=) |
| AU (1) | AU2016206707A1 (https=) |
| BR (1) | BR112017015136A2 (https=) |
| CA (1) | CA2973720A1 (https=) |
| WO (1) | WO2016115274A1 (https=) |
Families Citing this family (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| MA43874A (fr) * | 2016-01-13 | 2018-11-21 | Compass Therapeutics Llc | Constructions de liaison à l'antigène immunomodulateur multispécifique |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| AU2017252233A1 (en) | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| MX2018014950A (es) * | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| SI3468586T1 (sl) | 2016-06-14 | 2025-01-31 | Xencor, Inc. | Bispecifična protitelesa za zaviralce kontrolnih točk |
| WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| AU2017321625A1 (en) * | 2016-08-30 | 2019-04-04 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| BR112019005895A2 (pt) | 2016-09-23 | 2019-06-11 | Merus N.V. | moléculas de ligação que modulam uma atividade biológica expressa por uma célula |
| US20190225701A1 (en) * | 2016-09-26 | 2019-07-25 | The Brigham And Women's Hospital, Inc. | Regulators of b cell-mediated immunosuppression |
| CN109790215B (zh) | 2016-09-29 | 2023-06-30 | 北京韩美药品有限公司 | 异源二聚体免疫球蛋白构建体和其制备方法 |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CN106632681B (zh) | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| JP7031810B2 (ja) * | 2016-11-18 | 2022-03-08 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド | 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| WO2018120843A1 (zh) * | 2016-12-30 | 2018-07-05 | 上海近岸生物科技有限公司 | 一种三功能分子及其应用 |
| BR112019013189A2 (pt) * | 2017-01-03 | 2019-12-10 | Hoffmann La Roche | moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa |
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3053275A1 (en) * | 2017-02-10 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Proteins binding psma, nkg2d and cd16 |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| IL268836B2 (en) * | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| CN120173123A (zh) | 2017-02-27 | 2025-06-20 | 蜻蜓疗法股份有限公司 | 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白 |
| CN106939050B (zh) * | 2017-03-27 | 2019-05-10 | 顺昊细胞生物技术（天津）股份有限公司 | 抗pd1和cd19双特异性抗体及其应用 |
| CN107043425B (zh) * | 2017-03-27 | 2019-05-10 | 顺昊细胞生物技术（天津）股份有限公司 | 抗pd1和cd20双特异性抗体及其应用 |
| CN106986939B (zh) * | 2017-03-27 | 2019-06-07 | 顺昊细胞生物技术（天津）股份有限公司 | 抗pd-1和tem-8双特异性抗体及其应用 |
| CA3059769A1 (en) * | 2017-04-28 | 2018-11-01 | Elstar Therapeutics, Inc. | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof |
| MX2019013998A (es) * | 2017-05-23 | 2020-07-29 | Dragonfly Therapeutics Inc | Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2). |
| JP2020522254A (ja) | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス， インコーポレイテッド | 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用 |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| TWI828625B (zh) * | 2017-06-25 | 2024-01-11 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質以及彼之製造及使用方法 |
| SG11201913137VA (en) | 2017-07-11 | 2020-01-30 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| SG11202000503QA (en) | 2017-07-20 | 2020-02-27 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| AU2018322178A1 (en) * | 2017-08-23 | 2020-02-20 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| SG10202102502VA (en) * | 2017-09-07 | 2021-04-29 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| TW201930358A (zh) * | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對ｔｉｇｉｔ之單域抗體及其變異體 |
| US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| WO2019153200A1 (zh) * | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| WO2019164930A1 (en) * | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| AU2019228128A1 (en) * | 2018-03-02 | 2020-09-03 | Cdr-Life Ag | Trispecific antigen binding proteins |
| WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210008113A1 (en) * | 2018-03-27 | 2021-01-14 | Systimmune, Inc. | Methods of making and using guidance and navigation control proteins |
| WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| BR112020020828A2 (pt) * | 2018-04-13 | 2021-01-19 | Affimed Gmbh | Proteínas de ligação, composições farmacêuticas, método para o tratamento ou melhoria de uma doença, para tratar e/ou prevenir uma doença, para tratar um paciente e para tratar câncer e anticorpos |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| EP3790585A4 (en) * | 2018-05-07 | 2022-05-11 | Dragonfly Therapeutics, Inc. | PROTEIN-BINDING NKG2D, CD16 AND TUMOR-ASSOCIATED ANTIGEN |
| KR20210020903A (ko) | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| WO2019222449A1 (en) * | 2018-05-16 | 2019-11-21 | Dragonfly Therapeutics, Inc. | Protein binding nkg2d, cd16 and a fibroblast activation protein |
| WO2019226658A1 (en) * | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
| CA3099308A1 (en) * | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| WO2019224385A2 (en) * | 2018-05-24 | 2019-11-28 | Glenmark Pharmaceuticals S.A. | Combined bispecific antibody and immuno-oncology therapies |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| US20220041713A1 (en) * | 2018-09-18 | 2022-02-10 | Pandion Operations, Inc | Targeted immunotolerance |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| EP3861016A2 (en) | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| CN111196856A (zh) * | 2018-11-19 | 2020-05-26 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| AU2020226904B2 (en) | 2019-02-21 | 2025-05-01 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| WO2020172601A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| EP3927745A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| UA128825C2 (uk) | 2019-03-01 | 2024-10-30 | Ксенкор, Інк. | Гетеродимерні антитіла, що зв'язують enpp3 та cd3 |
| WO2020205504A1 (en) * | 2019-03-29 | 2020-10-08 | Compass Therapeutics Llc | Common light chains and methods of use |
| US12404331B2 (en) | 2019-04-19 | 2025-09-02 | Tcrcure Biopharma Corp. | Anti-PD-1 antibodies and uses thereof |
| US12516128B2 (en) * | 2019-05-14 | 2026-01-06 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| CA3285695A1 (en) * | 2019-06-26 | 2026-03-02 | Ap Biosciences, Inc. | Antibodies for t-cell activation |
| EP4013446A1 (en) * | 2019-08-16 | 2022-06-22 | The Regents of the University of California | Combined cancer therapy involving chemical activation of integrins and targeted cell immunotherapy |
| CN114502203B (zh) * | 2019-11-06 | 2024-07-19 | 成都百利多特生物药业有限责任公司 | 制导和导航控制蛋白及其制备和使用方法 |
| CN114829408B (zh) | 2019-12-20 | 2024-01-26 | 山东博安生物技术股份有限公司 | 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂 |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2021139780A1 (en) * | 2020-01-10 | 2021-07-15 | Shanghai Henlius Biotech, Inc. | Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same |
| KR102559355B1 (ko) * | 2020-01-31 | 2023-07-25 | 주식회사 제넥신 | 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
| JP7784039B2 (ja) * | 2020-03-31 | 2025-12-11 | 公立大学法人大阪 | 多重特異性抗体及びその製造方法 |
| GB2612450A (en) | 2020-04-24 | 2023-05-03 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| WO2021222595A2 (en) * | 2020-04-30 | 2021-11-04 | Virtuoso Binco, Inc. | Multispecific antibodies targeting cd38 and epcam and uses thereof |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| EP4168451A2 (en) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| WO2022002112A1 (en) | 2020-07-01 | 2022-01-06 | Shandong Boan Biotechnology Co., Ltd. | Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody |
| CN114057882B (zh) * | 2020-07-31 | 2023-01-06 | 山东博安生物技术股份有限公司 | 多价多特异性抗体 |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| AU2021331076A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| CA3190755A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20230074487A (ko) | 2020-08-26 | 2023-05-30 | 마렝고 테라퓨틱스, 인크. | Trbc1 또는 trbc2를 검출하는 방법 |
| WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| US20240218065A1 (en) * | 2021-06-15 | 2024-07-04 | Shenghe (China) Biopharmaceutical Co. | Multispecific antigen-binding protein and use thereof |
| US20240327543A1 (en) * | 2021-08-02 | 2024-10-03 | Shenghe (China) Biopharmaceutical Co., Ltd. | Multispecific antigen-binding protein and use thereof |
| US20240336682A1 (en) * | 2021-08-02 | 2024-10-10 | Shenghe (China) Biopharmaceutical Co., Ltd. | Multispecific antigen-binding protein and use thereof |
| CN119744270A (zh) * | 2022-07-08 | 2025-04-01 | 盛禾(中国)生物制药有限公司 | 一种异源二聚体融合蛋白及其应用 |
| WO2024028386A1 (en) * | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2025082429A1 (zh) * | 2023-10-17 | 2025-04-24 | 普米斯生物技术(珠海)有限公司 | 针对ccr8和ctla4的双特异性抗体 |
| AR134514A1 (es) | 2023-12-01 | 2026-01-21 | Gilead Sciences Inc | Proteína de fusión anti-fap-ligera y uso de esta |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2026011013A1 (en) | 2024-07-02 | 2026-01-08 | Epibiologics, Inc. | Binding agents and uses thereof |
| WO2026037839A2 (en) | 2024-08-12 | 2026-02-19 | ONA Therapeutics S.L. | Anti-fgfr4 molecules and uses thereof |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101289511A (zh) * | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| CA2511013A1 (en) * | 2002-12-20 | 2004-07-15 | Biogen Idec Ma Inc. | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| WO2008027236A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| KR20100058509A (ko) * | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| PE20120591A1 (es) * | 2009-04-02 | 2012-05-23 | Roche Glycart Ag | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla |
| EP3165540A1 (en) * | 2010-04-13 | 2017-05-10 | Celldex Therapeutics, Inc. | Antibodies that bind human cd27 and uses thereof |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012040518A2 (en) * | 2010-09-22 | 2012-03-29 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| WO2014100490A1 (en) * | 2012-12-19 | 2014-06-26 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| SG11201704741PA (en) * | 2014-12-22 | 2017-07-28 | Systimmune Inc | Bispecific tetravalent antibodies and methods of makiing and using thereof |
| EP3288975A1 (en) * | 2015-04-29 | 2018-03-07 | Institute for Research in Biomedicine | Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof |
| MA43874A (fr) * | 2016-01-13 | 2018-11-21 | Compass Therapeutics Llc | Constructions de liaison à l'antigène immunomodulateur multispécifique |
-
2016
- 2016-01-13 WO PCT/US2016/013291 patent/WO2016115274A1/en not_active Ceased
- 2016-01-13 CN CN201680012450.XA patent/CN107614522A/zh active Pending
- 2016-01-13 JP JP2017556515A patent/JP2018503399A/ja not_active Withdrawn
- 2016-01-13 BR BR112017015136A patent/BR112017015136A2/pt not_active Application Discontinuation
- 2016-01-13 US US15/543,542 patent/US20180318417A1/en not_active Abandoned
- 2016-01-13 EP EP16737835.5A patent/EP3245227A4/en not_active Withdrawn
- 2016-01-13 AU AU2016206707A patent/AU2016206707A1/en not_active Abandoned
- 2016-01-13 CA CA2973720A patent/CA2973720A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503399A5 (https=) | ||
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP2019509055A5 (https=) | ||
| US12029761B2 (en) | Guidance and Navigation Control proteins and method of making and using thereof | |
| JP6840682B2 (ja) | 多重特異的抗原結合タンパク質 | |
| JP2020500540A5 (https=) | ||
| JP2019513725A5 (https=) | ||
| WO2014165818A2 (en) | Compositions and methods for preventing and treating prostate cancer | |
| CA3030760A1 (en) | Humanized antibody against o-acetylated gd2 ganglioside (oacgd2) | |
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| CA2936244A1 (en) | Compositions and methods for modulating and redirecting immune responses | |
| CN115066274A (zh) | 三价结合分子 | |
| JP2021520201A5 (https=) | ||
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| CA3058262A1 (en) | Chimeric polypeptides and methods of altering the membrane localization of the same | |
| TWI896517B (zh) | 雙專一性抗體及製造與使用其的方法 | |
| US20230002488A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| CA3173176A1 (en) | Anti-tumor associated antigen antibodies and uses thereof | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| EP3091031A1 (en) | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor | |
| CN119997975A (zh) | 抗cldn4-抗cd137双特异性抗体通过与pd-1信号抑制剂的组合在癌症治疗中的应用 | |
| WO2024037628A1 (zh) | 一种双特异性抗体及其应用 | |
| JPWO2022072601A5 (https=) | ||
| CN119365484A (zh) | 修饰的细胞毒性t细胞及其使用方法 |